ABSTRACT
Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) are popular antimalarial drugs that also exhibit wide range of activities against other diseases such as cancer, diabetes, HIV, and microbial infections, among others. They are also reported to possess antioxidant properties. The popularity of these drugs skyrocketed with the emergence of coronavirus disease 2019 (COVID-19) that has caused the deaths of over 600,000,000 people worldwide just within 7 months. Due to the urgency of the time in discovering or repurposing new drugs that will be active against SARS-CoV-2, the causative agent of COVID-19, some initial in vitro studies found prospects in CQ and HCQ against SARS-CoV-2. HCQ instantly became a drug of choice over CQ for the treatment of COVID-19 patients because it is readily absorbed and less toxic. However, clinical studies found no positive indices to support the continued use of HCQ. This chapter looks into this by consulting current literatures in order to unravel the myth surrounding the approval and disapproval of the use of HCQ. © 2022 Elsevier Inc. All rights reserved.